REGEN BIOPHARMA, INC. (RGBPP) Total liabilities 2017–2025
REGEN BIOPHARMA, INC. (RGBPP) total liabilities at each fiscal year-end, per SEC filings.
$6.6MFY2025 · since FY2017: $6.2M → $6.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $6.6M | +21.9% |
| FY2024 | $5.4M | -1.5% |
| FY2023 | $5.5M | -36.5% |
| FY2022 | $8.6M | -41.5% |
| FY2021 | $14.7M | +97.1% |
| FY2020 | $7.5M | -32.2% |
| FY2019 | $11.0M | +18.0% |
| FY2018 | $9.3M | +50.6% |
| FY2017 | $6.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RGBPP financial trends
RGBPP RevenueRGBPP Net incomeRGBPP Net marginRGBPP Gross profitRGBPP Gross marginRGBPP Operating incomeRGBPP Operating marginRGBPP Operating cash flowRGBPP Free cash flowRGBPP Capital expendituresRGBPP Return on equityRGBPP Stock buybacksRGBPP Dividends paidRGBPP Total assetsRGBPP Shareholders’ equityRGBPP overview →